Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Introduction: We investigated the renoprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on renal function in patients with type 2 diabetes and chronic kidney disease (CKD) with normoalbuminuria. Methods: A retrospective review of clinical records of Japanese participants with...

Full description

Bibliographic Details
Main Authors:	Kiyohiko Takahashi, Akinobu Nakamura, Sho Furusawa, Kei Yokozeki, Hajime Sugawara, Hideyuki Yanagisawa, Kazumasa Akikawa, Hideaki Kikuchi
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	Journal of Clinical & Translational Endocrinology
Subjects:	Chronic kidney disease Diabetic kidney disease Normoalbuminuria Sodium-glucose cotransporter 2 inhibitor Type 2 diabetes
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214623720300971

Similar Items

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
by: Akinobu Nakamura, et al.
Published: (2020-01-01)

Perbedaan Kadar Liver Fatty Acid Binding Protein (L-FABP) Urine Penderita Diabetes Melitus Tipe 2 dengan Normoalbuminuria dan Mikroalbuminuria
by: Kristina Wiharjo, et al.
Published: (2014-06-01)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
by: Tomoaki Takata, et al.
Published: (2021-04-01)

A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion
by: Satoru Kuriyama
Published: (2019-07-01)

Detection of Lower Albuminuria Levels and Early Development of Diabetic Kidney Disease Using an Artificial Intelligence-Based Rule Extraction Approach
by: Yoichi Hayashi
Published: (2019-09-01)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
by: Kota Yano, et al.
Published: (2020-02-01)

The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors
by: Yi-Hsin Chan, et al.
Published: (2021-08-01)

Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
by: Jing Xu, et al.
Published: (2021-06-01)

Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
by: Hideaki Miyoshi, et al.
Published: (2019-11-01)

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
by: Hirai K, et al.
Published: (2020-01-01)

Sodium–glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice
by: Taro Hirai, et al.
Published: (2021-09-01)

Association between Grade of Normoalbuminuria and Left Ventricular Diastolic Dysfunction (LVDD) in Hypertensive Population of Gunungsari Village, Pamijahan-Bogor, Indonesia
by: Nur Zamiatun Qomara, et al.
Published: (2019-08-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension
by: Aranzazu Santiago-Hernandez, et al.
Published: (2021-07-01)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
by: Hidekatsu Yanai, et al.
Published: (2021-04-01)

Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score‐matched model analysis in Japan
by: Kazuo Kobayashi, et al.
Published: (2021-08-01)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
by: Kyu Yong Cho, et al.
Published: (2021-07-01)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
by: Koki Chiba, et al.
Published: (2021-02-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Prevalence of subnormal glomerular filtration rate in patients with diabetes mellitus
by: I I Trofimenko, et al.
Published: (2008-06-01)

Non-Diabetic Kidney Disease in Type 2 Diabetic Patients: Prevalence, Clinical Predictors and Outcomes
by: Siyar Erdogmus, et al.
Published: (2017-11-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease
by: Suyan Duan, et al.
Published: (2021-06-01)

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
by: Takeshi Horii, et al.
Published: (2021-09-01)

Stronger Association of Albuminuria with the Risk of Vascular Complications than Estimated Glomerular Filtration Rate in Type 2 Diabetes
by: Xinyu Hong, et al.
Published: (2021-08-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)
by: Sun H. Kim, et al.
Published: (2020-07-01)

Mechanisms and clinical significance of nephroprotective action of sodium-glucose cotransporter 2 inhibitors
by: I. Y. Pchelin, et al.
Published: (2019-01-01)

Diabetic kidney disease versus non-diabetic kidney disease in type 2 diabetic patients on dialysis: An observational cohort
by: Cerasuolo, D., et al.
Published: (2022)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
by: Adel E. Berbari
Published: (2020-12-01)

Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes
by: Yan Xie, et al.
Published: (2021-06-01)

Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
by: Baodi Xing, et al.
Published: (2020-09-01)

Impact of Type 2 Diabetes on Impaired Kidney Function in Sub-Saharan African Populations
by: Sally N Adebamowo, et al.
Published: (2016-05-01)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01)

Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study
by: Ken Kanazawa, et al.
Published: (2019-07-01)

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
by: Alexis Diaz-Ramos, et al.
Published: (2019-09-01)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
by: Reed JW
Published: (2016-10-01)

Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy
by: Sonia Mota-Zamorano, et al.
Published: (2021-09-01)

Cannot write session to /tmp/vufind_sessions/sess_810hrh3q9hvc3ntm98laud5ton